approvals, Canada - Aug., p. 236
approvals, European countries - May, p. 136, 137; June, p. 168; Aug., p. 235; Sep., p. 264; Oct., p. 298
approvals, Thailand - Sep., p. 261
approvals, U.S. - Feb., p. 41; Mar., p. 65, 66, 67, 76; Apr., p. 105, 106, 97; May, p. 131, 141; June, p. 162, 170; July, p. 205; Sep., p. 257; Oct., p. 289, 291, 292; Nov., p. 323, 324, 334
clinical trials - Feb., p. 33, 35, 37, 38, 39, 40, 41, 42, 43, 44; Mar., p. 66, 67, 68, 69, 70, 71, 73, 74, 75; Apr., p. 97, 99, 100, 101, 102, 103, 104; May, p. 129, 130, 132, 134, 135, 136, 138, 140, 141; June, p. 161, 163, 165, 166, 167, 168, 170, 172; July, p. 193, 195, 198, 201, 202, 203; Aug., p. 225, 227, 228, 229, 234, 236; Sep., p. 258, 260, 263, 264, 265, 267; Oct., p. 289, 291, 292, 294, 295, 296, 297, 298, 299, 300, 301; Nov., p. 324, 325, 326, 328, 329, 332, 333, 334; Dec., p. 360, 361, 362, 363, 364, 365, 366
Collaborative Research & Development Agreements (CRADAs) - Mar., p. 73, 74, 75; June, p. 169; July, p. 193
corporate linkages - Feb., p. 39; Mar., p. 78; Apr., p. 104; May, p. 133, 134, 135, 137, 139, 140; June, p. 164, 166, 168, 170; July, p. 202, 204; Aug., p. 233; Sep., p. 265, 266, 269; Oct., p. 298, 300; Nov., p. 331, 333; Dec., p. 359, 367
development halted - Feb., p. 38; June, p. 165, 172; July, p. 197; Aug., p. 226; Sep., p. 259, 262
expanded access - Apr., p. 102; Aug., p. 232, 233; Sep., p. 258; Nov., p. 333; Dec., p. 366
insider trading - June, p. 172
licensing - Feb., p. 39, 46; Mar., p. 75; Apr., p. 107, 108; May, p. 137; June, p. 174; July, p. 200, 206; Aug., p. 236, 238, 239; Sep., p. 265, 271; Oct., p. 301; Nov., p. 335, 336; Dec., p. 367
Medicaid - Apr., p. 105; May, p. 139; Dec., p. 366
new viruses - Sep., p. 264; Nov., p. 331
patent disputes - Feb., p. 46; Mar., p. 75; Apr., p. 106, 107; May, p. 142; Aug., p. 239
warning letters, FDA - Mar., p. 76; May, p. 140; June, p. 172; Nov., p. 332
Web sites - Feb., p. 45; Mar., p. 77; July, p. 205; Nov., p. 335